Iovance Biotherapeutics Inc [NASDAQ: IOVA] closed the trading session at $2.3 on 2025-09-16. The day’s price range saw the stock hit a low of $2.24, while the highest price level was $2.38.
The stocks have a year to date performance of -75.69 percent and weekly performance of -2.95 percent. The stock has been moved at -38.50 percent over the last six months. The stock has performed -9.80 percent around the most recent 30 days and changed 10.58 percent over the most recent 3-months.
If compared to the average trading volume of 16.49M shares, IOVA reached to a volume of 9101780 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Iovance Biotherapeutics Inc [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $9.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 2.08. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Iovance Biotherapeutics Inc shares, keeping their opinion on the stock as Sell, with their previous recommendation back on July 15, 2025. The new note on the price target was released on May 16, 2025, representing the official price target for Iovance Biotherapeutics Inc stock.
The Price to Book ratio for the last quarter was 1.13, with the Price to Cash per share for the same quarter was set at 0.83.
IOVA stock trade performance evaluation
Iovance Biotherapeutics Inc [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.95. With this latest performance, IOVA shares dropped by -9.80% in over the last four-week period, additionally sinking by -38.50% over the last 6 months – not to mention a drop of -68.92% in the past year of trading.
Iovance Biotherapeutics Inc [IOVA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Iovance Biotherapeutics Inc [IOVA] shares currently have an operating margin of -170.02% and a Gross Margin at 10.81%. Iovance Biotherapeutics Inc’s Net Margin is presently recorded at -161.44%.
Iovance Biotherapeutics Inc (IOVA) Capital Structure & Debt Analysis
According to recent financial data for Iovance Biotherapeutics Inc. ( IOVA), the Return on Equity (ROE) stands at -53.16%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -41.66%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Iovance Biotherapeutics Inc’s Return on Invested Capital (ROIC) is -52.44%, showcasing its effectiveness in deploying capital for earnings.
Iovance Biotherapeutics Inc (IOVA) Efficiency & Liquidity Metrics
Based on Iovance Biotherapeutics Inc’s (IOVA) latest financial statements, the Debt-to-Equity Ratio is 0.08%, indicating its reliance on debt financing relative to shareholder equity.
Iovance Biotherapeutics Inc (IOVA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Iovance Biotherapeutics Inc. (IOVA) effectively leverages its workforce, generating an average of -$465298.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.27% and a Quick Ratio of 2.89%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Iovance Biotherapeutics Inc [IOVA] stock
With the latest financial reports released by the company, Iovance Biotherapeutics Inc posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.3/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IOVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Iovance Biotherapeutics Inc go to 50.61%.
Iovance Biotherapeutics Inc [IOVA]: Institutional Ownership
There are presently around $69.33%, or 69.58%% of IOVA stock, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 25.95 million shares, which is approximately 9.1113%. PERCEPTIVE ADVISORS LLC, holding 25.93 million shares of the stock with an approximate value of $$207.98 million in IOVA stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$192.46 million in IOVA stock with ownership which is approximately 8.4254%.
